These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 22667455)

  • 1. Extended spectrum β-lactamases, carbapenemases and mobile genetic elements responsible for antibiotics resistance in Gram-negative bacteria.
    El Salabi A; Walsh TR; Chouchani C
    Crit Rev Microbiol; 2013 May; 39(2):113-22. PubMed ID: 22667455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria.
    Bush K; Fisher JF
    Annu Rev Microbiol; 2011; 65():455-78. PubMed ID: 21740228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options.
    Jean SS; Lee WS; Lam C; Hsu CW; Chen RJ; Hsueh PR
    Future Microbiol; 2015; 10(3):407-25. PubMed ID: 25812463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains.
    Rossolini GM; Mantengoli E; Docquier JD; Musmanno RA; Coratza G
    New Microbiol; 2007 Jul; 30(3):332-9. PubMed ID: 17802921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
    Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Carbapenemases in gram-negative bacteria. Current data and trends of resistance resulting from the work of national reference centres].
    Kaase M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Nov; 55(11-12):1401-4. PubMed ID: 23114438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug-resistant Gram-negative bacteria: a product of globalization.
    Hawkey PM
    J Hosp Infect; 2015 Apr; 89(4):241-7. PubMed ID: 25737092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and emergence of carbapenemases-producing Gram-negative bacteria in Mediterranean basin.
    Mathlouthi N; Al-Bayssari C; Bakour S; Rolain JM; Chouchani C
    Crit Rev Microbiol; 2017 Feb; 43(1):43-61. PubMed ID: 27387224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases.
    Shah AA; Hasan F; Ahmed S; Hameed A
    Res Microbiol; 2004; 155(6):409-21. PubMed ID: 15249058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metallo-β-lactamases and class D carbapenemases in south-east Tunisia: Implication of mobile genetic elements in their dissemination.
    Dziri O; Alonso CA; Dziri R; Gharsa H; Maraoub A; Torres C; Chouchani C
    Int J Antimicrob Agents; 2018 Dec; 52(6):871-877. PubMed ID: 29909172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of Carbapenem Resistance Mechanisms Among Gram-Negative Pathogens in Lebanon: Results of the First Cross-Sectional Countrywide Study.
    Hammoudi Halat D; Moubareck CA; Sarkis DK
    Microb Drug Resist; 2017 Sep; 23(6):733-743. PubMed ID: 28080212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A high prevalence of multi-drug resistant Gram-negative bacilli in a Nepali tertiary care hospital and associated widespread distribution of Extended-Spectrum Beta-Lactamase (ESBL) and carbapenemase-encoding genes.
    Manandhar S; Zellweger RM; Maharjan N; Dongol S; Prajapati KG; Thwaites G; Basnyat B; Dixit SM; Baker S; Karkey A
    Ann Clin Microbiol Antimicrob; 2020 Oct; 19(1):48. PubMed ID: 33087115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].
    Hrabák J
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):103-11. PubMed ID: 17900058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology and Management of Emerging Drug-Resistant Gram-Negative Bacteria: Extended-Spectrum β-Lactamases and Beyond.
    Boyle DP; Zembower TR
    Urol Clin North Am; 2015 Nov; 42(4):493-505. PubMed ID: 26475946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-lactamase-mediated resistance: a biochemical, epidemiological and genetic overview.
    Gutkind GO; Di Conza J; Power P; Radice M
    Curr Pharm Des; 2013; 19(2):164-208. PubMed ID: 22894615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic diversity and risk factors for the transmission of antimicrobial resistance across human, animals and environmental compartments in East Africa: a review.
    Katale BZ; Misinzo G; Mshana SE; Chiyangi H; Campino S; Clark TG; Good L; Rweyemamu MM; Matee MI
    Antimicrob Resist Infect Control; 2020 Aug; 9(1):127. PubMed ID: 32762743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [News of antibiotic resistance among Gram-negative bacilli in Algeria].
    Baba Ahmed-Kazi Tani Z; Arlet G
    Pathol Biol (Paris); 2014 Jun; 62(3):169-78. PubMed ID: 24819127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging resistance in Gram-negative pathogens and implications for clinical practice.
    Cantón R; Lumb J
    Future Microbiol; 2011 Jan; 6(1):19-22. PubMed ID: 21162632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular basis of β-lactamase production in Gram-negative bacteria from Saudi Arabia.
    Yezli S; Shibl AM; Memish ZA
    J Med Microbiol; 2015 Feb; 64(Pt 2):127-136. PubMed ID: 25418734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance phenotypes and genotypes in Mexico in representative gram-negative species: Results from the infivar network.
    Garza-González E; Bocanegra-Ibarias P; Bobadilla-Del-Valle M; Ponce-de-León-Garduño LA; Esteban-Kenel V; Silva-Sánchez J; Garza-Ramos U; Barrios-Camacho H; López-Jácome LE; Colin-Castro CA; Franco-Cendejas R; Flores-Treviño S; Morfín-Otero R; Rojas-Larios F; Mena-Ramírez JP; Fong-Camargo MG; Morales-De-la-Peña CT; García-Mendoza L; Choy-Chang EV; Aviles-Benitez LK; Feliciano-Guzmán JM; López-Gutiérrez E; Gil-Veloz M; Barajas-Magallón JM; Aguirre-Burciaga E; López-Moreno LI; Martínez-Villarreal RT; Canizales-Oviedo JL; Cetina-Umaña CM; Romero-Romero D; Bello-Pazos FD; Barlandas-Rendón NRE; Maldonado-Anicacio JY; Bolado-Martínez E; Galindo-Méndez M; Perez-Vicelis T; Alavez-Ramírez N; Méndez-Sotelo BJ; Cabriales-Zavala JF; Nava-Pacheco YC; Moreno-Méndez MI; García-Romo R; Silva-Gamiño AR; Avalos-Aguilera AM; Santiago-Calderón MA; López-García M; Velázquez-Acosta MDC; Cobos-Canul DI; Vázquez-Larios MDR; Ortiz-Porcayo AE; Guerrero-Núñez AE; Valero-Guzmán J; Rosales-García AA; Ostos-Cantú HL; Camacho-Ortiz A
    PLoS One; 2021; 16(3):e0248614. PubMed ID: 33730101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.